Data as of November 12, 2026

Amlodipine-Valsartan-Hydrochlorothiazide 10-160-25 mg Tab

AMLODIPINE BESYLATE VALSARTAN HYDROCHLOROTHIAZIDE

Brand: AMLODIPINE, VALSARTAN, HYDROCHLOROTHIAZIDE

Acquisition price (NADAC) is as of October 21, 2026. Medicaid reimbursement figures are from 2024, the most recent year in CMS's published claims data. The two are not contemporaneous — treat any comparison as directional, not exact.

Price per fill

NADAC (acquisition)
$310.41/ fill$6.11 / EA
Cost Plus Drugs (retail)
$238.00/ fill$4.69 / EA
FUL
$544.99/ fill$10.73 / EA
AMP
$311.43/ fill$6.13 / EA
Medicaid FFS
$415.18/ fill
Medicaid MCO
$326.23/ fill

Sources: cms/nadac:price-ladder · costplusdrugs/price-list · cms/ful:generic-ceiling · cms/sdud. Cost Plus prices as of 2026-11-12

What's in the reimbursement

Ingredient cost (50.8 units/fill)$310.41
Dispensing fee & other (state-fixed, not margin)$104.77
Total reimbursed per fill$415.18

The gap above stays roughly flat across drugs regardless of acquisition cost — that's the professional dispensing fee, a fixed per-fill amount the state pays every pharmacy, not a markup.

Medicaid volume backing this card: 2 fee-for-service states, 4 managed-care states.

Full methodology and source columns: /tools/drug-prices/methodology

Sources: acquisition prices from CMS's National Average Drug Acquisition Cost survey, effective 2026-10-28; utilisation from CMS State Drug Utilization Data, 2024; Cost Plus Drugs prices from their published price list. NADAC and SDUD vintages differ. Every number links to how it was calculated. Full methodology